中华放射肿瘤学杂志
中華放射腫瘤學雜誌
중화방사종류학잡지
CHINESE JOURNAL OF RADIATION ONCOLOGY
2013年
1期
13-16
,共4页
孙帅%张福泉%胡克%侯晓荣%沈捷%连欣%晏俊芳%刘志凯
孫帥%張福泉%鬍剋%侯曉榮%瀋捷%連訢%晏俊芳%劉誌凱
손수%장복천%호극%후효영%침첩%련흔%안준방%류지개
宫颈肿瘤/同期放化疗%调强放射治疗%近距离疗法%预后
宮頸腫瘤/同期放化療%調彊放射治療%近距離療法%預後
궁경종류/동기방화료%조강방사치료%근거리요법%예후
Cervical neoplasms/concurrent radiochemotherapy%Iintensity modulated radiotherapy%Brachytherapy%Prognosis
目的 回顾分析宫颈癌术后患者调强放疗(IMRT)同期化疗的生存率、局部控制率及不良反应.方法 2005-2009年宫颈癌术后病理至少有1项预后不良因素的115例患者入组.盆腔IMRT 96例、扩大野19例,临床靶体积中位剂量50.4 Gy分28次;阴道残段高剂量率内照射参考点位于阴道黏膜下0.5 cm,驻留1 cm或1/2阴道长度,中位剂量为15 Gy;97例同期每周40 mg/m2顺铂化疗.结果 所有患者均顺利完成治疗,随访率为94.8%.全组2年和3年总生存率分别为94.2%和86.0%、无瘤生存率分别为84.2%和76.7%、盆腔控制率分别为96.0%和87.8%;40例出现3~4级骨髓抑制,1例出现3级急性直肠反应,无≥3级泌尿系反应.100例患者8周内完成放化疗,2例出现≥3级慢性直肠反应,3例患者出现下肢水肿.结论 宫颈癌术后具有不良预后因素者术后IMRT同期化疗具有较好的局部控制率及较低的不良反应.
目的 迴顧分析宮頸癌術後患者調彊放療(IMRT)同期化療的生存率、跼部控製率及不良反應.方法 2005-2009年宮頸癌術後病理至少有1項預後不良因素的115例患者入組.盆腔IMRT 96例、擴大野19例,臨床靶體積中位劑量50.4 Gy分28次;陰道殘段高劑量率內照射參攷點位于陰道黏膜下0.5 cm,駐留1 cm或1/2陰道長度,中位劑量為15 Gy;97例同期每週40 mg/m2順鉑化療.結果 所有患者均順利完成治療,隨訪率為94.8%.全組2年和3年總生存率分彆為94.2%和86.0%、無瘤生存率分彆為84.2%和76.7%、盆腔控製率分彆為96.0%和87.8%;40例齣現3~4級骨髓抑製,1例齣現3級急性直腸反應,無≥3級泌尿繫反應.100例患者8週內完成放化療,2例齣現≥3級慢性直腸反應,3例患者齣現下肢水腫.結論 宮頸癌術後具有不良預後因素者術後IMRT同期化療具有較好的跼部控製率及較低的不良反應.
목적 회고분석궁경암술후환자조강방료(IMRT)동기화료적생존솔、국부공제솔급불량반응.방법 2005-2009년궁경암술후병리지소유1항예후불량인소적115례환자입조.분강IMRT 96례、확대야19례,림상파체적중위제량50.4 Gy분28차;음도잔단고제량솔내조사삼고점위우음도점막하0.5 cm,주류1 cm혹1/2음도장도,중위제량위15 Gy;97례동기매주40 mg/m2순박화료.결과 소유환자균순리완성치료,수방솔위94.8%.전조2년화3년총생존솔분별위94.2%화86.0%、무류생존솔분별위84.2%화76.7%、분강공제솔분별위96.0%화87.8%;40례출현3~4급골수억제,1례출현3급급성직장반응,무≥3급비뇨계반응.100례환자8주내완성방화료,2례출현≥3급만성직장반응,3례환자출현하지수종.결론 궁경암술후구유불량예후인소자술후IMRT동기화료구유교호적국부공제솔급교저적불량반응.
Objective To investigate the survival rate,local control rate,and toxicity rate in postoperative cervical cancer patients who receive concurrent chemotherapy and intensity-modulated radiotherapy (IMRT) by retrospective analysis.Methods From September 2005 to May 2009,115 postoperative cervical cancer patients,who had at least one poor prognostic factor as evaluated by pathological examination,were included in the study.Of all the patients,96 received IMRT to the whole pelvic cavity,and 19 extended-field IMRT.The clinical target volume received a median dose of 50.4 Gy/28 fractions in all patients.High-dose-rate vaginal cuff brachytherapy (0.5 cm below the vaginal mucosa)was performed at an active length of 1 cm or half of the vaginal length and a median dose of 15 Gy.Ninety patients received chemotherapy with cisplatin (4 0 mg/m2) as well as IMRT on a weekly basis.Results Treatment was completed successfully in all patients.The follow-up rate was 94.8%.In all the patients,the 2-and 3-year overall survival rates were 94.2% and 86.0%,with disease-free survival rates of 84.2% and 76.7% and pelvic control rates of 96.0% and 87.8% ;40 patients developed grade 3-4 myelosuppression,1 patient developed grade 3 acute rectal toxicity,and none developed grade ≥3 urinary toxicity.Of the 100 patients who finished radiotherapy and chemotherapy within 8 weeks,2 developed grade ≥3 chronic rectal toxicity,and 3 developed lower extremity edema.Conclusions The postoperative cervical cancer patients with poor prognostic factors who undergo postoperative concurrent chemotherapy and MRT can achieve high local control rate and low toxicity rate.